argenx NV ADR

ARGX · Moat type: REGULIERUNG

MoatScore

8/10

Fair Value

546 USD

Margin of Safety

-57.0 %

Rating

BEOBACHTEN

argenx NV develops and markets antibody therapies based on its FcRn-blocking technology (efgartigimod), which reduces pathological IgG antibodies in autoimmune diseases, and generates revenues primarily through the sale of approved medicines as well as complementary milestone and licensing payments from partnership agreements.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.